Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 48 (PPIAP48) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to that of the functional peptidylprolyl isomerase A gene (PPIA), but it is not believed to encode an active protein product. Pseudogenes typically arise through gene duplication or retrotransposition events and usually accumulate disabling mutations, so they do not have the molecular or biological functions found in protein-coding genes. PPIAP48 is not known to have any therapeutic relevance as a drug or biomarker target, and there is no evidence linking it to disease mechanisms or drug interactions. Its inclusion as a target is incorrect because pseudogenes are not recognized as conventional targets (such as receptors, enzymes, transporters, etc.) for drug therapy. This designation should be flagged as potentially incorrect if included among functional therapeutic targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 48 (PPIAP48).